Woodline Partners’s Opus Genetics IRD Stock Holding History
Bought
Maintained
Sold
Other funds holding IRD
Woodline Partners's IRD Position: Q3 2026 in Review
Woodline Partners reduced its Opus Genetics (IRD) stake by 54% in Q3 2026, selling an estimated $3.21M and leaving 661,729 shares worth $3.2M. The position accounts for 0.01% of the portfolio, ranked #813.
Woodline Partners first reported a position in IRD in Q1 2026 and has held it in 3 quarters since. The position peaked at $6.16M in Q1 2026. 112 funds tracked by Wall St. Rank hold IRD as of Q3 2026.
- Woodline Partners held 661,729 shares of Opus Genetics worth $3.2M as of Q3 2026.
- Woodline Partners sold 772,984 Opus Genetics shares in Q3 2026, an estimated $3.21M.
- Opus Genetics made up 0.01% of Woodline Partners's portfolio in Q3 2026, its #813 holding.
- Woodline Partners first reported a position in Opus Genetics in Q1 2026 and has held it in 3 quarters since.
- Woodline Partners's Opus Genetics position peaked at $6.16M in Q1 2026.
- 112 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2026.
Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.